54 research outputs found
Transcriptome changes in age-related macular degeneration
Age-related macular degeneration (AMD) is a debilitating, common cause of visual impairment. While the last decade has seen great progress in understanding the pathophysiology of AMD, the molecular changes that occur in eyes with AMD are still poorly understood. In the current issue of Genome Medicine, Newman and colleagues present the first systematic transcriptional profile analysis of AMD-affected tissues, providing a comprehensive set of expression data for different regions (macula versus periphery), tissues (retina versus retinal pigment epithelium (RPE)/choroid), and disease state (control versus early or advanced AMD). Their findings will serve as a foundation for additional systems-level research into the pathogenesis of this blinding disease
Analysis of copy number variation at DMBT1 and age-related macular degeneration
BACKGROUND:
DMBT1 is a gene that shows extensive copy number variation (CNV) that alters the number of bacteria-binding domains in the protein and has been shown to activate the complement pathway. It lies next to the ARMS2/HTRA1 genes in a region of chromosome 10q26, where single nucleotide variants have been strongly associated with age-related macular degeneration (AMD), the commonest cause of blindness in Western populations. Complement activation is thought to be a key factor in the pathogenesis of this condition. We sought to investigate whether DMBT1 CNV plays any role in the susceptibility to AMD.
METHODS:
We analysed long-range linkage disequilibrium of DMBT1 CNV1 and CNV2 with flanking single nucleotide polymorphisms (SNPs) using our previously published CNV and HapMap Phase 3 SNP data in the CEPH Europeans from Utah (CEU). We then typed a large cohort of 860 AMD patients and 419 examined age-matched controls for copy number at DMBT1 CNV1 and CNV2 and combined these data with copy numbers from a further 480 unexamined controls.
RESULTS:
We found weak linkage disequilibrium between DMBT1 CNV1 and CNV2 with the SNPs rs1474526 and rs714816 in the HTRA1/ARMS2 region. By directly analysing copy number variation, we found no evidence of association of CNV1 or CNV2 with AMD.
CONCLUSIONS:
We have shown that copy number variation at DMBT1 does not affect risk of developing age-related macular degeneration and can therefore be ruled out from future studies investigating the association of structural variation at 10q26 with AMD
Genetic polymorphism of the iron-regulatory protein-1 and -2 genes in age-related macular degeneration
Iron can be involved in the pathogenesis of AMD through the oxidative stress because it may catalyze the Haber–Weiss and Fenton reactions converting hydrogen peroxide to free radicals, which can induce cellular damage. We hypothesized that genetic polymorphism in genes related to iron metabolism may predispose individuals to the development of AMD and therefore we checked for an association between the g.32373708 G>A polymorphism (rs867469) of the IRP1 gene and the g.49520870 G>A (rs17483548) polymorphism of the IRP2 gene and AMD risk as well as the modulation of this association by some environmental and life-style factors. Genotypes were determined in DNA from blood of 269 AMD patients and 116 controls by the allele-specific oligonucleotide-restriction fragment length polymorphism and the polymerase chain reaction-restriction fragment length polymorphism. An association between AMD, dry and wet forms of AMD and the G/G genotype of the g.32373708 G>A-IRP1 polymorphism was found (OR 3.40, 4.15, and 2.75). On the other hand, the G/A genotype reduced the risk of AMD as well as its dry or wet form (OR 0.23, 0.21, 0.26). Moreover, the G allele of the g.49520870 G>A-IRP2 polymorphism increased the risk of the dry form of the disease (OR 1.51) and the A/A genotype and the A allele decreased such risk (OR 0.43 and 0.66). Our data suggest that the g.32373708 G>A-IRP1 and g.49520870 G>A-IRP2 polymorphisms may be associated with increased risk for AMD
Topical dorzolamide treatment of macular cysts in the enhanced S-cone syndrome patient
A needs assessment for a minor eye condition service within Leeds, Bradford and Airedale, UK
YesBackground: There are a number of limitations to the present primary eye care system in the UK. Patients with
minor eye conditions typically either have to present to their local hospital or GP, or face a charge when visiting
eye care professionals (optometrists). Some areas of the UK have commissioned enhanced community services to
alleviate this problem; however, many areas have not. The present study is a needs assessment of three areas
(Leeds, Airedale and Bradford) without a Minor Eye Conditions Service (MECS), with the aim of determining whether
such a service is clinically or economically viable.
Method: A pro forma was developed for optometrists and practice staff to complete when a patient presented whose
reason for attending was due to symptoms indicative of a problem that could not be optically corrected. This form
captured the reason for visit, whether the patient was seen, the consultation funding, the outcome and where the
patient would have presented to if the optometrists could not have seen them. Optometrists were invited to
participate via Local Optical Committees. Results were submitted via a Google form or a Microsoft Excel document and
were analysed in Microsoft Excel.
Results: Seventy-five percent of patients were managed in optometric practice. Nine and 16% of patients required
subsequent referral to their General Practitioner or hospital ophthalmology department, respectively. Should they not
have been seen, 34% of patients would have presented to accident and emergency departments and 59% to their
general practitioner. 53% of patients paid privately for the optometrist appointment, 28% of patients received a free
examination either through use of General Ophthalmic Service sight tests (9%) or optometrist good will (19%) and
19% of patients did not receive a consultation and were redirected to other providers (e.g. pharmacy, accident and
emergency or General Practitioner). 88% of patients were satisfied with the level of service. Cost-analyses revealed a
theoretical cost saving of £3198 to the NHS across our sample for the study period, indicating cost effectiveness.
Conclusions: This assessment demonstrates that a minor eye condition service in the local areas would be economically
and clinically viable and well received by patients
Regulatory regions of the paraoxonase 1 (PON1) gene are associated with neovascular age-related macular degeneration (AMD)
Physiological stress response and oxidative damage are factors for aging processes and, as such, are thought to contribute to neovascular age-related macular degeneration (AMD). Paraoxonase 1 (PON1) is an enzyme that plays an important role in oxidative stress and aging. We investigated association of DNA sequence variants (SNP) within the upstream regulatory region of the PON1 gene with neovascular AMD in 305 patients and 288 controls. Four of the seven tested SNPs (rs705379, rs705381, rs854573, and rs757158) were more frequently found in AMD patients compared to controls (P = 0.0099, 0.0295, 0.0121, and 0.0256, respectively), and all but one (SNP rs757158) are in linkage disequilibrium. Furthermore, haplotype TGGCCTC conferred protection (odds ratio (OR) = 0.76, (CI) = 0.60-0.97) as it was more frequently found in control individuals, while haplotype CGATGCT increased the risk (OR = 1.55, CI = 1.09-2.21) for AMD. These results were also reflected when haplotypes for the untranscribed and the 5'untranslated regions (5'UTR) were analyzed separately. To assess haplotype correlation with levels of gene expression, the three SNPs within the 5'UTR were tested in a luciferase reporter assay. In retinal pigment epithelium-derived ARPE19 cells, we were able to measure significant differences in reporter levels, while this was not observed in kidney-derived HEK293 cells. The presence of the risk allele A (SNP rs705381) caused an increase in luciferase activity of approximately twofold. Our data support the view that inflammatory reactions mediated through anti-oxidative activity may be relevant to neovascular age-related macular degeneration
No difference in serum sialic acid in Type 2 diabetic patients from the United Arab Emirates with and without diabetic retinopathy
12 month visual outcome data for patients treated with Bevacizumab (Avastin) for neovascular age-related macular degeneration
- …